REFERENCES
  1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardization of terminology in lower urinary tract function: Report from the standardization sub-committee of the International Continence Society. Urology. 2003;61(1):37–49.
  2. Turner WH, Brading AF. Smooth muscle of the bladder in the normal and the diseased state: Pathophysiology, diagnosis, and treatment. Pharmacol Ther. 1997;75(2):77–110.
  3. Bates CP, Whiteside CG, Turner‐Warwick R. synchronous cine/pressure/flow/cystourethrography with special reference to stress and urge incontinence. Br J Urol. 1970;42(6):714-23.
  4. Benner JS, Nichol MB, Rovner ES, Jumadilova Z, Alvir J, Hussein M, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010;105(9):1276–82.
  5. Homma Y, Gotoh M, Kawauchi A, et al. Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia. Int J Urol . 2017;24(10):716-729.
  6. Yamaguchi O. Beta3-adrenoceptors in human detrusor muscle. Urology . 2002;59(5 Suppl 1):25-29.
  7. Ichihara K, Masumori N, Fukuta F, Tsukamoto T, Iwasawa A, Tanaka Y. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. J Urol. 2015;193(3):921–6.
  8. Kakizaki H, Lee KS, Yamamoto O, Jong JJ, Katou D, Sumarsono B, et al. Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH). Eur Urol Focus. 2019;1–9.
  9. Kaplan SA, Herschorn S, McVary KT, et al. Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS). J Urol . 2020; 203(6):1163-1171.
  10. Su Shunye, Lin J, Liang L, Liu L, Chen Z, Gao Y. The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: A systematic review and meta-analysis. Medicine (Baltimore) . 2020; 99(4):e18802.
  11. Matsuo T, Miyata Y, Kakoki K, Yuzuriha M, Asai A, Ohba K, et al. The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: Prospective analysis of elderly men. BMC Urol. 2016;16(1):1–7.
  12. Wada N, Iuchi H, Kita M, Hashizume K, Matsumoto S, Kakizaki H. Urodynamic Efficacy and Safety of Mirabegron Add-on Treatment with Tamsulosin for Japanese Male Patients with Overactive Bladder.LUTS: Lower Urinary Tract Symptoms  2016;8(3):171–6.
  13. Lee M. Tamsulosin for the treatment of benign prostatic hypertrophy. Ann Pharmacother . 2000; (2):188-199.
  14. Lee SW, Doo SW, Yang WJ, Song YS. Importance of relieving the most bothersome symptom for improving quality of life in male patients with lower urinary tract symptoms. Urology . 2012; 80(3):684-687.
  15. Kuo HC, Lee KS, Na Y, et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourol Urodyn 2015; 34(7):685-692.
  16. Oelke M, Speakman MJ, Desgrandchamps F, Mamoulakis C. Acute Urinary Retention Rates in the General Male Population and in Adult Men With Lower Urinary Tract Symptoms Participating in Pharmacotherapy Trials: A Literature Review. Urol2015; 86(4):654-665.
  17. Drake MJ, MacDiarmid S, Al-Shukri S, et al. Adding Mirabegron to Solifenacin to Treat Overactive Bladder Has Little Impact on Postvoid Residual Volume or Urinary Retention Risk. Urol2017; 104:1-4.
  18. Sudrania MK, Dangi AD, Kumar S, Kumar B, Kekre NS. Urodynamic outcomes of tamsulosin in the treatment of primary bladder neck obstruction in men. Ind J Urol 2018; 34:34-8.
  19. Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA2006; 296:2319-2328.
  20. Kaplan SA, McCammon K, Fincher R, et al. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J.Urol 2009; 182: 2825-2830.
  21. MacDiarmid SA, Peters KM, Chen A, et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin Proc. 2008; 83: 1002-1010.
  22. Yamaguchi O, Kakizaki H, Homma Y, et al. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms ASSIST, randomized controlled study. Urol2011; 78:126-133.
  23. Alexandre EC, Kiguti LR, Calmasini FB, Silva FH, Silva KP, Ferreira R and et al.Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3 -adrenoceptor activation and α1 -adrenoceptor blockade. Br J Pharmacol 2016;173:415–428.
  24. Singh I, TK Aravind, Gupta S. Efficacy andsafety of tadalafil vs tamsulosin in lower urinary tractsymptoms (LUTS) as a result of (BPH)—open label randomised controlled study. Int J ClinPract. 2020;00:e13530.
  25. Singh DV, Mete UK, Mandal AK, Singh SK. A comparative randomized prospectivestudy to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to BPH. J Sex Med. 2014;11(1):187-96.
  26. Takahashi S, Kato D, Tabuchi H, Uno S. Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: A Japanese post‐marketing study. LUTS 2020;1–9.DOI: 10.1111/luts.12335
  27. Shin DG, Kim HW, YoonSJ, et al. Mirabegron as a treatment for overactivebladder symptoms in men (MIRACLE study):Efficacy and safety results from a multicenter,randomized, double-blind, placebo-controlled,parallel comparison phase IV study. NeuroUrol Urodynamics. 2018;1–10.
  28. Singh I, Agarwal V, Garg G. ’Tamsulosin and Darifenacin’ Versus ’TamsulosinMonotherapy’ for ’BPH with Accompanying Overactive Bladder’. J Clin Diag Res2015;9(6):PC08-11.
LEGENDS FOR FIG & TABLES :
Fig 1: Figure depicting the flow of the current study protocol
Table 1 (a-b): Table 1a depicting the baseline and demographic features of the patient parameters and Table 1b depicting the post treatment parameters of the same in the two groups.
Table 2: Depicting a summary of mirabegron comparative studies on BPH induced OABS. Table 3 (a-c): Table 3 depicting a comparison previous similar study designs with the present studywith respect to OABSS total score improvement (Table3a); IPSS-ss score improvement (Table 3b) and change in the PVR (Table 3c) in both the patient groups.